Form 424B5 MARINUS PHARMACEUTICALS,
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Marinus Pharmaceuticals (MRNS) PT Lowered to $22 at Jefferies
November 9, 2022 8:04 AM ESTJefferies analyst Andrew Tsai lowered the price target on Marinus Pharmaceuticals (NASDAQ: MRNS) to $22.00 (from $29.00) while maintaining a Buy rating.
The analyst commented, "We think the ongoing launch of Ztalmy (oral ganaxolone; GNX) in CDD rare-epilepsy ($100M+ peak sales) is executing... More
